# Richard S. Finkel

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/richard-s-finkel/

## Facts

| Field | Value |
| --- | --- |
| Citations | 32,686 |
| Field | Neurogenetic and Muscular Disorders Research |
| h-index | 85 |
| i10-index | 245 |
| Last Known Institution | St. Jude Children's Research Hospital |
| OpenAlex ID | https://openalex.org/A5084459237 |
| ORCID iD | https://orcid.org/0000-0002-9351-7054 |
| Works | 468 |

## Researcher papers

- [Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy](https://scholariq.org/papers/nusinersen-versus-sham-control-in-infantile-onset-spinal-muscular-atrophy/)
- [Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy](https://scholariq.org/papers/nusinersen-versus-sham-control-in-later-onset-spinal-muscular-atrophy/)
- [Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care](https://scholariq.org/papers/diagnosis-and-management-of-spinal-muscular-atrophy-part-1-recommendations-for/)
- [Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics](https://scholariq.org/papers/diagnosis-and-management-of-spinal-muscular-atrophy-part-2-pulmonary-and-acute/)
- [Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study](https://scholariq.org/papers/nusinersen-initiated-in-infants-during-the-presymptomatic-stage-of-spinal/)
- [Agalsidase-Beta Therapy for Advanced Fabry Disease](https://scholariq.org/papers/agalsidase-beta-therapy-for-advanced-fabry-disease/)
- [Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ataluren-in-patients-with-nonsense-mutation-duchenne-muscular-dystrophy-act-dmd/)
- [Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial](https://scholariq.org/papers/onasemnogene-abeparvovec-for-presymptomatic-infants-with-two-copies-of-smn2-at/)
- [Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial](https://scholariq.org/papers/onasemnogene-abeparvovec-for-presymptomatic-infants-with-three-copies-of-smn2-at/)
- [Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes](https://scholariq.org/papers/biallelic-mutations-in-sord-cause-a-common-and-potentially-treatable-hereditary/)

## Researcher topics

- [Neurogenetic and Muscular Disorders Research](https://scholariq.org/topics/neurogenetic-and-muscular-disorders-research/)
- [Muscle Physiology and Disorders](https://scholariq.org/topics/muscle-physiology-and-disorders/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)
- [Cardiomyopathy and Myosin Studies](https://scholariq.org/topics/cardiomyopathy-and-myosin-studies/)
- [Hereditary Neurological Disorders](https://scholariq.org/topics/hereditary-neurological-disorders/)

## Researcher university

- [St. Jude Children's Research Hospital](https://scholariq.org/institutions/st-jude-children-s-research-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.